A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Company Overview The Beauty Health Company (the “Company” or “we”) is a medtech meets beauty company that delivers skin health experiences that help consumers reinvent their relationship with their skin, bodies, and self-confidence. The Company and its subsidiaries design, develop, manufacture, market, and sell esthetic technologies and products. The Company’s brands are pioneers: Hydrafacial in hydradermabrasion; SkinStylus in nanoneedling and microneedling; and Keravive in scalp health. Together, with its powerful global community of estheticians, partners, and consumers, the Company is personalizing skin health for all ages, genders, skin tones, and skin types. Our Brands The following chart reflects our brand portfolio: Hydrafacial is our flagship brand and cornerstone of our portfolio.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 302M | 334M | 398M | 366M | 260M | 119M |
| Net Income | -12M | -29M | -100M | 44M | -375M | -29M |
| EPS | $-0.16 | $-0.36 | $-0.76 | $-0.23 | $-3.67 | $-0.85 |
| Free Cash Flow | 39M | 15M | 18M | -117M | -40M | -16M |
| ROIC | -4.4% | -4.8% | -12.5% | 4.9% | -28.1% | -15.7% |
| Gross Margin | 64.8% | 54.5% | 39.0% | 68.0% | 69.9% | 56.4% |
| Debt/Equity | 0.00 | 10.66 | 12.43 | 4.39 | 2.41 | -7.21 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -28M | -68M | -131M | -26M | -37M | -17M |
| Operating Margin | -9.3% | -20.3% | -32.9% | -7.1% | -14.1% | -14.4% |
| ROE | -17.9% | -52.3% | -168.6% | 26.5% | -124.1% | - |
| Shares Outstanding | 128M | 81M | 132M | 123M | 102M | 151M |
| Metric | 2020 | 2021 | 2022 | |||
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 119M | 260M | 366M | 398M | 334M | 302M |
| Gross Margin | 56.4% | 69.9% | 68.0% | 39.0% | 54.5% | 64.8% |
| R&D | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -17M | -37M | -26M | -131M | -68M | -28M |
| Op. Margin | -14.4% | -14.1% | -7.1% | -32.9% | -20.3% | -9.3% |
| Net Income | -29M | -375M | 44M | -100M | -29M | -12M |
| Net Margin | -24.5% | -144.2% | 12.1% | -25.2% | -8.7% | -3.9% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | ||||||
| ROIC | -15.7% | -28.1% | 4.9% | -12.5% | -4.8% | -4.4% |
| ROE | N/A | -124.1% | 26.5% | -168.6% | -52.3% | -17.9% |
| ROA | -13.1% | -30.8% | 4.4% | -10.8% | -3.6% | -2.3% |
| Cash Flow | ||||||
| Op. Cash Flow | -12M | -28M | -107M | 22M | 16M | 39M |
| Free Cash Flow | -16M | -40M | -117M | 18M | 15M | 39M |
| Owner Earnings | -15M | -45M | -142M | -12M | -21M | 2.1M |
| CapEx | 3.5M | 11M | 11M | 3.8M | 756K | 238K |
| Maint. CapEx | 2.6M | 4.5M | 7.2M | 11M | 9.9M | 9.9M |
| Growth CapEx | 949K | 6.7M | 3.7M | 0 | 0 | 0 |
| D&A | 2.6M | 4.5M | 7.2M | 11M | 9.9M | 9.9M |
| CapEx/OCF | N/A | N/A | N/A | 17.6% | 4.7% | 0.6% |
| Capital Allocation | ||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 154K | 0 | 160M | 30M | 0 | 0 |
| Buyback Yield | 0.0% | N/A | 15.5% | 7.2% | N/A | 0.0% |
| Stock-Based Comp | 363K | 12M | 28M | 23M | 27M | 27M |
| Debt Repayment | 77K | 21M | 0 | 0 | 0 | 0 |
| Balance Sheet | ||||||
| Net Debt | 207M | -172M | 166M | 215M | 182M | -219M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | N/A | 219M |
| Long-Term Debt | 216M | 730M | 734M | 738M | 552M | 552M |
| Debt/Equity | -7.21 | 2.41 | 4.39 | 12.43 | 10.66 | 0.00 |
| Interest Coverage | -0.8 | -3.1 | -1.9 | -9.6 | -6.5 | -6.5 |
| Equity | -30M | 302M | 167M | 59M | 52M | 66M |
| Total Assets | 223M | 1.2B | 1.0B | 929M | 686M | 504M |
| Total Liabilities | 253M | 917M | 836M | 870M | 634M | 438M |
| Intangibles | 99M | 124M | 125M | 126M | 123M | 123M |
| Retained Earnings | -44M | -419M | -379M | -479M | -508M | -508M |
| Working Capital | 28M | 924M | 712M | 583M | 409M | 409M |
| Current Assets | 59M | 1.0B | 783M | 698M | 477M | 477M |
| Current Liabilities | 31M | 76M | 72M | 115M | 68M | 68M |
| Per Share Data | ||||||
| EPS | -0.85 | -3.67 | -0.23 | -0.76 | -0.36 | -0.16 |
| Owner EPS | -0.10 | -0.44 | -1.15 | -0.09 | -0.25 | 0.02 |
| Book Value | -0.20 | 2.96 | 1.35 | 0.45 | 0.64 | 0.51 |
| Cash Flow/Share | -0.08 | -0.28 | -0.86 | 0.17 | 0.20 | -0.01 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 150.6M | 102.2M | 123.4M | 131.7M | 80.8M | 127.5M |
| Valuation | ||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | -6.2 |
| P/FCF | N/A | N/A | N/A | 23.4 | 8.5 | 3.3 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 8.0 | 6.2 | 7.1 | 2.5 | 1.9 |
| Price/Sales | 13.5 | 7.1 | 4.6 | 2.7 | 0.6 | 0.4 |
| FCF Yield | -0.9% | -1.6% | -11.3% | 4.3% | 11.7% | 30.5% |
| Market Cap | 1.8B | 2.4B | 1.0B | 419M | 131M | 126M |
| Avg. Price | 10.67 | 18.04 | 13.52 | 8.19 | 2.31 | 0.99 |
| Year-End Price | 12.00 | 23.52 | 8.39 | 3.18 | 1.62 | 0.99 |
Beauty Health Co passes 3 of 9 quality checks, indicating weak fundamentals.
On a free-cash-flow basis, the stock trades at 3.3x vs a median of 15.9x. The company's 5-year average gross margin is 57.6%. At current prices, the estimated annualized return to fair value is +12.7%.
Beauty Health Co (SKIN) has a 5-year average return on invested capital (ROIC) of -11.3%. This is below average and may indicate limited pricing power.
Beauty Health Co (SKIN) has a market capitalization of $126M. It is classified as a small-cap stock.
Beauty Health Co (SKIN) does not currently pay a regular dividend.
Beauty Health Co (SKIN) operates in the Surgical & Medical Instruments & Apparatus industry, within the Healthcare sector.
Beauty Health Co (SKIN) reported annual revenue of $334 million in its most recent fiscal year, based on SEC EDGAR filings.
Beauty Health Co (SKIN) has a net profit margin of -8.7%. The company is currently unprofitable.
Beauty Health Co (SKIN) generated $15 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Beauty Health Co (SKIN) has a debt-to-equity ratio of 10.66. This indicates higher leverage, which may increase financial risk.
Beauty Health Co (SKIN) reported earnings per share (EPS) of $-0.36 in its most recent fiscal year.
Beauty Health Co (SKIN) has a return on equity (ROE) of -52.3%. A negative ROE may indicate losses or negative equity.
Beauty Health Co (SKIN) has a 5-year average gross margin of 57.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 5 years of financial data for Beauty Health Co (SKIN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Beauty Health Co (SKIN) has a book value per share of $0.64, based on its most recent annual SEC filing.
No recent press releases.